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Abstract
Background: In addition to their cholesterol lowering ability, statins have proven pleiotropic
effects in the cardiovascular system. Chronic inflammation with interactions between platelets
and endothelial cells leads to an upregulation of activity markers of atherosclerosis. The
purpose of this study was to investigate the effects of simvastatin and atorvastatin on platelets
and endothelial cells in an in vitro endothelial cell model.
Methods and Results: After a 24 h incubation period with either simvastatin or atorvastatin
(1 µmol/L), human umbilical vein endothelial cells were stimulated for 1 h with lipopolysac-
charide (LPS), and were then incubated in direct contact with activated platelets. Platelet
surface expression of CD40L and CD62P and expression of ICAM-1, VCAM-1, uPAR and
MT1-MMP on endothelial cells were measured by flow cytometry. Supernatants were analyzed
by ELISA for soluble MMP-1. The increased expression of VCAM-1 and uPAR on endothelial
cells by stimulation with LPS and by direct contact with activated platelets was significantly
reduced to a similar extent through pre-incubation with both atorvastatin and simvastatin
(p < 0.05). Platelets without endothelial cell contact, but in direct contact with either statin,
showed similar significant reductions in surface expression of CD40L (p < 0.005).
Conclusions: These effects may explain the ability of statins to reduce the progression of
atherosclerosis in addition to their cholesterol-lowering properties. (Cardiol J 2012; 19, 1: 20–28)
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Introduction
The pathogenesis of atherosclerosis, the lead-
ing cause of morbidity and mortality in industrial
countries, is multifactorial. Cardiovascular (CV) risk
factors such as hypertension, diabetes, cigarette
smoking, family history and elevated serum lipid
levels contribute to the initiation and progression
of atherosclerosis [1–5]. Interactions between plate-
lets and endothelium play an important role in the
pathogenesis of atherosclerosis and CV diseases,
leading to severe clinical events such as myocar-
dial infarction (MI) and stroke. It is characterized
by the formation of plaque consisting of foam cells,
immune cells, vascular endothelial cells, smooth
muscle cells, platelets, extracellular matrix and
a lipid-rich core [2, 6, 7]. Moreover, interactions be-
tween platelets and endothelial cells mediate essen-
tial processes in the development of atherosclero-
sis by an increased expression of vascular cell ad-
hesion molecules and their ligands [8–12]. CD62P
and CD40L are expressed on activated platelets and
are directly involved in the interaction of platelets
with leukocytes and endothelial cells [13]. Binding
of CD40L to endothelial CD40, which is the counter-
receptor for platelet-derived CD40L, leads to the
release of interleukin-8, tissue factor and MCP-1,
the major chemoattractants for neutrophils and
monocytes [14–16]. In addition, activation of CD40
on endothelial cells leads to increased expression
of various endothelial adhesion receptors such as
E-selectin, vascular cell adhesion molecule
(VCAM)-1 and intercellular adhesion molecule
(ICAM)-1 [17–19]. Upregulation of endothelial
VCAM-1 and ICAM-1 expression increases vulne-
rability of the atherosclerotic vascular plaque to fis-
suring rupture and superimposed thrombosis, lead-
ing to the clinical scenario of unstable angina, acute
MI or sudden cardiac death [20–22]. Engagement
of the endothelial CD40 receptor and platelet CD40L
results in an increased production of inflammatory
cytokines, adhesion molecules and matrix-degrading
proteases (MMPs). MMPs degrade various proteins
of the extracellular matrix and promote inflammation
and the destruction of the inflamed tissue. Addition-
ally, imbalance in the plasminogen and matrix metal-
loproteinase activation systems may lead to destabi-
lization of the vulnerable fibrous cap of the atheroscle-
rotic plaque [23–25].
Statins are highly effective lipid-lowering agents,
widely used in medical practice [26]. Simvastatin
and atorvastatin are representative of this class and
are commonly prescribed and applied statins. Hy-
percholesterolemia impairs endothelial function
and, by blocking 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA), statins inhibit an early rate-
limiting step in cholesterol biosynthesis [27]. Fur-
thermore, statins decrease smooth muscle cell mi-
gration and proliferation [28], decrease pre-pro
endothelin-1 (ET-1) mRNA expression and increase
basal nitric oxide dilator functions of the endothe-
lium [29]. Because of the strong association between
elevated serum cholesterol levels and coronary
atherosclerotic disease, it has been suggested that
the reduction of serum cholesterol levels by statins
is the main mechanism underlying their beneficial
effects [30].
However, recent evidence suggests that sta-
tins have pleiotropic effects, independent of lipid
balance regulation, and that this may partially explain
their role in decreasing CV mortality and morbidity.
The influence of statin treatment on various soluble
cellular adhesion molecules (CAMs), including
ICAM-1, has already been described in hypercholes-
terolemic patients [31]. Pleiotropic statin effects may
be due to an attenuation of interactions between
platelets and vascular endothelial cells and the re-
lease and expression of activity markers of athero-
sclerosis. Therefore, the purpose of the present
study was to investigate the effects of simvastatin
and atorvastatin on platelets and endothelial cells in
an in vitro endothelial cell model.
Methods
Coincubation of simvastatin or atorvastatin
pre-incubated endothelial cells with platelets
Human umbilical vein endothelial cells (HU-
VEC) were prepared as previously described [32,
33] and cultured in endothelial cell basal medium
(PromoCell) containing 2% fetal calf serum (FCS);
1 µg/mL hydrocortisone (HC-500); 0.4% endothe-
lial cell growth supplement (ECGS/H-2); 0.1 ng/mL
epidermal growth factor (hEGF-0.05); 1 ng/mL ba-
sic fibroblast growth factor (hbFGF-0.5); 5 ng/mL
amphotericin and 50 µg/mL gentamicin. The con-
fluenced endothelial cells were added to 12-well
plates and incubated for 24 h with 1 mmol/L nico-
tinic acid (Merck, Hohenbrunn, Germany). Plate-
lets were prepared from the blood of healthy
probands as described [34, 35]. Washed platelets
were stimulated for 30 min with thrombin (0.5 U/mL)
and lipopolysaccharide (LPS) (1,000 ng/mL). Before
coincubation experiments, thrombin activity was
antagonized by hirudin (5 U/mL). Pretreated plate-
lets (final concentration 2 × 108/mL) were added
to confluent endothelial monolayers with and with-
out nicotinic acid. After 60-min coincubation under
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cell culture conditions, all platelets were removed
by gentle washing, which was confirmed by light mi-
croscopy. After six more hours of incubation of the
endothelial cells, the supernatant was aspirated,
centrifuged at 2,000 g and stored at –80°C [36]. Fol-
lowing this incubation, the expression of activity
markers on platelets, as well as that on endothelial
cells, was measured by flow cytometry.
Flow cytometric analysis
Flow cytometric analysis of platelets and en-
dothelial cells was performed by gating in forward
and side scatter. Platelets were gated back for de-
termination of the expression of CD40L and CD62P.
For the analysis of platelets, 100 µL of each sample
were stained for 15 min at room temperature with
10 µL aliquots of mouse anti-human CD40L-FITC
antibodies (BD Pharmingen, Heidelberg, Germany)
and mouse anti-human CD62P-PE antibodies
(Beckman-Coulter, Krefeld, Germany).  Endothe-
lial cells were gated back for determination of the
surface expression of ICAM-1, VCAM-1, urokinase
receptor uPAR and membrane type 1 matrix me-
talloprotease (MT1-MMP). For the analysis of en-
dothelial cells, 100 µL of each sample were stained
for 15 min at room temperature with 10 µL aliquots
of anti-human CD54 PE-Cy5 (ICAM-1 from BD
Pharmingen, Heidelberg, Germany), anti-human
CD106-FITC (VCAM-1 from R&D Systems, Inc.,
Wiesbaden, Germany), anti-human CD87-FITC
(uPAR from American Diagnostica Inc., Stamford,
CT, USA), anti-human MT1-MMP (Ab-1) Mouse
mAb (114-IF2) (Merck Chemicals Ltd., Nottingham,
UK). Corresponding isotypes (Beckman Coulter,
Marseille, France) were used as a control. All flow
cytometric analyses were performed on an EPICS
XL-MCL analyzer (Beckman Coulter, Krefeld, Ger-
many) equipped with an argon laser tuned at 488 nm.
Mean fluorescence intensity was measured and
all FACS data is expressed as MFI in this manu-
script. System II Version 3.0 software was used for
data acquisition and evaluation. Compensation of
the four channel fluorescence was adjusted for pre-
cision using Cyto-CompTM reagents and Cyto-
TrolTM control cells (Coulter Immunotech,
Krefeld, Germany).
Enzyme linked immunosorbent assay
(ELISA)
The concentration of MMP-1 (Human, Biotrak
ELISA System, GE Healthcare Ltd, UK) in the su-
pernatants was determined by sandwich-type im-
munoassay following the manufacturer’s instruc-
tions. All concentration analyses were performed
on an ELISA-Reader — Lab Systems Multiskan RC
(Labsystems, Finland). Genesis Lite Software,
ELISA Multiskan RC was used for data acquisition
and evaluation.
Statistical analysis
All calculations were performed using SAS re-
lease 9.2 (SAS Institute Inc. Cary, NC, USA). Nu-
merical data was expressed as means ± standard
deviation. A Dunnett’s test was applied as paramet-
ric test. A two-tailed probability value < 0.05 was
considered significant.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Results
Effects of simvastatin and atorvastatin
on endothelial cell surface markers
HUVEC pre-incubation with simvastatin re-
sulted in significantly decreased surface expression
of VCAM-1 from 1.37 ± 0.57 to 0.69 ± 0.05 (p =
= 0.013) after contact with resting platelets, and
from 1.26 ± 0.4 to 0.69 ± 0.07 (p = 0.007) after
contact with thrombin-stimulated platelets. Pre-in-
cubation with simvastatin significantly reduced sur-
face expression of VCAM-1 from 1.4 ± 0.6 to 0.66 ±
± 0.05 (p = 0.014) after contact with LPS-stimu-
lated platelets, and from 1.4 ± 0.66 to 0.7 ± 0.1
(p = 0.03) after contact with LPS- and thrombin-
-stimulated platelets (Fig. 1).
HUVEC pre-incubation with simvastatin re-
sulted in significantly decreased surface expression
of uPAR from 0.4 ± 0.1 to 0.27 ± 0.04 (p = 0.038)
after contact with platelets, and from 0.56 ± 0.17
to 0.33 ± 0.06 (p = 0.035) after contact with throm-
bin-stimulated platelets. Pre-incubation with sim-
vastatin significantly reduced surface expression of
uPAR from 0.46 ± 0.13 to 0.27 ± 0.04 (p = 0.015)
after contact with LPS-stimulated platelets (Fig. 2).
HUVEC pre-incubation with atorvastatin result-
ed in significantly decreased surface expression of
VCAM-1 from 1.37 ± 0.57 to 0.7 ± 0.2 (p = 0.01)
after contact with platelets, and from 1.26 ± 0.4 to
0.68 ± 0.12 (p = 0.007) after contact with thrombin-
-stimulated platelets. Pre-incubation with atorvas-
tatin significantly reduced surface expression of
VCAM-1 from 1.4 ± 0.6 to 0.57 ± 0.12 (p = 0.008)
after contact with LPS-stimulated platelets, and from
1.4 ± 0.66 to 0.55 ± 0.18 (p = 0.01) after contact
with LPS- and thrombin-stimulated platelets (Fig. 1).
HUVEC pre-incubation with atorvastatin re-
sulted in significantly decreased surface expression
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Figure 1. Surface expression of VCAM-1 on HUVEC with and without 24 h pre-incubation with simvastatin or
atorvastatin; N = 7 experiments; PLT — platelets; Thr — thrombin; LPS — lipopolysaccharide; *p < 0.05 against not
pre-treated HUVEC; #p < 0.05 against not pre-treated HUVEC.
Figure 2. Surface expression of uPAR on HUVEC with and without 24 h pre-incubation with simvastatin or atorvasta-
tin; N = 7 experiments; PLT — platelets; Thr — thrombin; LPS — lipopolysaccharide; *p < 0.05 against not pre-
treated HUVEC; #p < 0.05 against not pre-treated HUVEC.
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of uPAR from 0.4 ± 0.1 to 0.27 ± 0.04 (p = 0.03)
after contact with platelets, and from 0.56 ± 0.17
to 0.32 ± 0.079 (p = 0.02) after contact with throm-
bin-stimulated platelets. Pre-incubation with ator-
vastatin significantly reduced surface expression of
uPAR from 0.46 ± 0.13 to 0.25 ± 0.05 (p = 0.007)
after contact with LPS-stimulated platelets, and from
0.55 ± 0.22 to 0.3 ± 0.08 (p = 0.03) after contact
with LPS- and thrombin-stimulated platelets (Fig. 2).
Regarding ICAM-1 expression on HUVEC,
pre-incubation with simvastatin significantly in-
creased surface expression of ICAM-1 from 21.03 ±
± 10.7 to 67.44 ± 11.5 (p = 0.0051) after contact
with platelets, and from 26.5 ± 14.2 to 52.32 ±
± 20.25 (p = 0.049) after contact with thrombin-
stimulated platelets (Fig. 3). Additionally, pre-in-
cubation with atorvastatin significantly increased
surface expression of ICAM-1 from 21.03 ± 10.7
to 76 ± 25.8 (p = 0.0018) after contact with plate-
lets, and from 57.3 ± 25.9 to 133.7 ± 50.9 (p = 0.02)
after contact with LPS-stimulated platelets (Fig. 3).
Simvastatin or atorvastatin had no significant
effects on the surface expression of MT1-MMP on
endothelial cells.
In a comparison between simvastatin and ator-
vastatin, we also observed no significant differenc-
es in their effects on human umbilical vein endo-
thelial cell surface markers.
Endothelial cell mediated and
direct effects of simvastatin and
atorvastatin on platelets
Platelet surface expression of CD62P did not
differ significantly between platelets in direct con-
tact with simvastatin or atorvastatin pre-incubated
endothelial cells compared to platelets incubated
with untreated endothelial cells (Fig. 4). Surface
expression of CD40L on platelets after one hour’s
direct contact with HUVECs, pre-incubated with
simvastatin, and stimulated with LPS, significantly
decreased from 1.99 ± 0.09 to 1.66 ± 0.26 (p =
= 0.0038) (Fig. 4). To discriminate between those
effects mediated by pre-treated endothelial cells and
the possible direct effects of simvastatin or ator-
vastatin on platelets, platelets were directly incubat-
ed with either simvastatin or atorvastatin solely for
1 h. When this was done, simvastatin incubation
significantly increased CD62P expression on un-
stimulated platelets from 0.99 ± 0.1 to 1.31 ± 0.13
(p = 0.0012), and atorvastatin incubation signifi-
cantly increased CD62P expression on unstimu-
lated platelets from 0.99 ± 0.1 to 1.21 ± 0.12
(p = 0.01), and when stimulated with LPS
and thrombin from 4.43 ± 3.14 to 6.78 ± 0.7
(p = 0.0047) (Fig. 5). Surface expression of CD40L
on platelets under stimulation with LPS was sig-
nificantly reduced by simvastatin from 2.14 ± 0.19
Figure 3. Surface expression of ICAM-1 on HUVEC with and without 24 h pre-incubation with simvastatin or
atorvastatin; N = 7 experiments; PLT — platelets; Thr — thrombin; LPS — lipopolysaccharide; NS — not significant;
*p < 0.05 against not pre-treated HUVEC; #p < 0.05 against not pre-treated HUVEC.
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Figure 4. Surface expression of CD62P (A) and CD40L (B) on platelets after 1 h of direct contact with HUVECs, with
and without pre-incubation with simvastatin or atorvastatin; N = 7 experiments; PLT — platelets; Thr — thrombin;
LPS — lipopolysaccharide; NS — not significant; *p < 0.05 vs non pre-treated platelets.
to 1.72 ± 0.06 (p = 0.0002) and by atorvastatin from
2.14 ± 0.19 to 1.69 ± 0.11 (p < 0.0001) (Fig. 5).
In a comparison between simvastatin and ator-
vastatin, we observed no significant differences in
their individual effects on platelet surface markers.
Effects of simvastatin and atorvastatin on
HUVEC supernatant levels of soluble MMP-1
Upon direct HUVEC stimulation with interleu-
kin 1b, supernatant levels of MMP-1 were lower
on HUVEC pre-treated with simvastatin (1.97 ±
Figure 5. Direct effects of simvastatin or atorvastatin on surface expression of CD62P (A) and CD40L (B) on platelets.
Platelets were directly incubated with simvastatin or atorvastatin for 1 h and stimulated with lipopolysaccharide (LPS)
and/or thrombin (Thr); N = 7 experiments; PLT — platelets; NS — not significant; *p < 0.05 vs non pre-treated
platelets; #p < 0.05 vs non pre-treated platelets.
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± 1.38 ng/mL; p = 0.39) and with atorvastatin
(3.06 ± 1.23 ng/mL; p = 0.55) compared to untrea-
ted HUVEC (5.22 ± 5.15 ng/mL), although these
differences were not statistically significant (Fig. 6).
Discussion
Many clinical studies, as well as data from re-
cent experimental studies, have revealed that sta-
tins have additional effects beyond their serum cho-
lesterol-lowering properties and that statins modi-
fy various biological processes in the vessel wall
[12, 28–31, 37–43]. In the present study, simvasta-
tin and atorvastatin reduced the expression of pro-
atherogenic activity and progression markers on
platelets and endothelial cells under pro-inflamma-
tory conditions in an in vitro endothelial cell mo-
del. Simvastatin and atorvastatin both significantly
reduced the expression of VCAM-1 and uPAR on
endothelial cells after direct contact with activated
platelets and surface expression of CD40L on plate-
lets. These results underpin the extensive athero-
protective effects of statins, which may, in addition
to their lipid-lowering potential, contribute to the
inhibition of atherosclerosis progression.
The benefit of statin therapy appears to exceed
the cholesterol-lowering effect by blocking HMG-
-CoA reductase, possibly by protective effects on
endothelial nitric oxide bioactivity [29] and athero-
sclerotic plaque stabilization [28, 40, 41]. In addi-
tion, a recent study has shown that statins can sup-
press inflammatory response independently of
HMG-CoA reductase inhibition by means of bind-
ing directly to a novel regulatory site of the b2 inte-
grin via inhibiting leukocyte function antigen-1 [37].
The mechanism of anti-inflammatory properties of
statins was further described by Yoshida et al. [38],
who demonstrated that cerivastatin reduced mono-
cyte adhesion to vascular endothelium by decrea-
sing expression of integrins and actin polymeriza-
tion through inactivation of RhoA.
In 1990, Berk et al. [44] highlighted the role of
inflammation in coronary artery disease with an
elevation of C-reactive protein (CRP). In the CARE
trial, statins significantly decreased plasma hs-CRP
levels over a five-year period in patients who did
not experience recurrent coronary events. This em-
phasizes the direct anti-inflammatory potential of
statins [39]. These studies indicate that statins are
effective in decreasing systemic and vascular in-
flammation. The CD40-CD40L signalling pathway
plays a key role in the modulation of inflammatory
responses between vascular cells and platelets, in-
volving adhesion molecules, pro-inflammatory cy-
tokines and chemokines. Statins have been proven
to decrease CD40 expression and CD40-related
activation of vascular cells [40, 41]. Mosheimer et al.
[43] showed that activated platelets induce COX-2
expression in HUVEC, and that this effect can be
reversed by pre-incubation of platelets with ator-
vastatin; this effect is due to the down-regulation of
CD40L on activated platelets by atorvastatin. It is
worth noting that in the present study we were able
to support these previous findings: simvastatin and
atorvastatin induced a significant reduction of
CD40L expression on platelets, whereas no signi-
ficant individual differences between both statins
regarding CD40L platelet surface expression could
be observed. The simvastatin and atorvastatin in
vitro concentration applied in the present study was
1 µmol/L, which is within the range of effective se-
rum concentrations seen in clinical practice [42, 45].
A limited number of randomized controlled
clinical trials comparing the use of atorvastatin to
that of simvastatin have shown that atorvastatin is
more effective in reducing total cholesterol levels
and LDL-cholesterol levels, as well as the rate of
CV events [46–48]. Jacobson et al. [49] found in
a retrospective study that the risk of the first CV
event was significantly lower among patients in
whom atorvastatin, rather than simvastatin, had
been newly initiated. uPAR is present at increased
levels in atherosclerosis, and correlates directly
with CV disease severity [50].
In our study, atorvastatin and simvastatin both
significantly reduced the expression of VCAM-1 and
uPAR on endothelial cells and CD40L surface ex-
pression on platelets. However, we observed no
Figure 6. Supernatant levels of soluble MMP-1 upon
stimulation with interleukin 1b on HUVEC with and with-
out pre-incubation with simvastatin or atorvastatin;
NS — not significant.
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significant differences between the statins regard-
ing individual effects on human umbilical vein en-
dothelial cell and platelet surface markers. In the
ARMYDA-ACS study, Patti et al. [51] demonstrated
an increased expression of ICAM-1 and VCAM-1 af-
ter preloading with high dose atorvastatin and af-
ter percutaneous coronary intervention. A possible
explanation for the increased expression of ICAM-1
may be the periprocedural use of glycoprotein IIb/
/IIIa inhibitors. Our study also showed a significantly
increased expression of ICAM-1 on endothelial cells
preincubated with statins and after stimulation with
activated platelets. However, we cannot provide
detailed mechanistic insights as to why statins in-
creased the expression of ICAM-1 on endothelial
cells, but significantly decreased VCAM-1 effects.
Future studies will be needed to further explore the
possible mechanism which supports the influence
of statins on CV diseases.
Conclusions
We demonstrated that simvastatin and ator-
vastatin both extenuate the expression of proat-
herogenic markers on endothelial cells and plate-
lets under pro-inflammatory conditions. These ef-
fects may explain the ability of statins to reduce CV
events and progression of atherosclerosis in addi-
tion to their cholesterol-lowering properties.
Conflict of interest: none declared
References
1. Jahn J, Dalhoff K, Katus HA. Coronary artery disease: An in-
flammatory or infectious process. Basic Res Cardiol, 2000; 95
(suppl. 1): I59–I64.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclero-
sis. Circulation, 2002; 105: 1135–1143.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive pro-
tein and other markers of inflammation in the prediction of car-
diovascular disease in women. N Engl J Med, 2000; 342: 836–
–843.
4. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic
vascular disease. Basic Res Cardiol, 2005; 100: 93–101.
5. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated
low density lipoprotein uptake by macrophages: Implications for
atherosclerosis. Circulation, 2001; 103: 1194–1197.
6. Ruggeri ZM. Platelets in atherothrombosis. Nat Med, 2002; 8:
1227–1234.
7. Lusis AJ. Atherosclerosis. Nature, 2000; 407: 233–241.
8. Amirkhosravi A, Alexander M, May K et al. The importance of
platelets in the expression of monocyte tissue factor antigen
measured by a new whole blood flow cytometric assay. Thromb
Haemost, 1996; 75: 87–95.
9. Gotz AK, Zahler S, Stumpf P, Welsch U, Becker BF. Intracoro-
nary formation and retention of micro aggregates of leukocytes
and platelets contribute to postischemic myocardial dysfunction.
Basic Res Cardiol, 2005; 100: 413–421.
10. Kälsch T, Elmas E, Nguyen XD et al. Enhanced coagulation
activation by in vitro lipopolysaccharide challenge in patients
with ventricular fibrillation complicating acute myocardial in-
farction. J Cardiovasc Electrophysiol, 2005; 16: 858–863.
11. Kälsch T, Nguyen XD, Elmas E et al. Coagulation activation and
expression of CD40 ligand on platelets upon in vitro lipopolysac-
charide-challenge in patients with unstable angina. Int J Cardiol,
2006; 111: 217–223.
12. Steiner S, Speidl WS, Pleiner J et al. Simvastatin blunts
endotoxin-induced tissue factor in vivo. Circulation, 2005; 111:
1841–1846.
13. Gawaz M. Role of platelets in coronary thrombosis and reperfu-
sion of ischemic myocardium. Cardiovasc Res, 2004; 61: 498–511.
14. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated
platelets triggers an inflammatory reaction of endothelial cells.
Nature, 1998; 391: 591–594.
15. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Bio-
chem Cell Biol, 2000; 32: 687–693.
16. Reed GL. Platelet secretory mechanisms. Semin Thromb He-
most, 2004; 30: 441–450.
17. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Re-
duction of atherosclerosis in mice by inhibition of CD40 signal-
ling. Nature, 1998; 394: 200–203.
18. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular
endothelial growth factor expression of intercellular adhesion
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1),
and E-selectin through nuclear factor-kappa b activation in endo-
thelial cells. J Biol Chem, 2001; 276: 7614–7620.
19. Davies MJ, Gordon JL, Gearing AJ et al. The expression of the
adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin
in human atherosclerosis. J Pathol, 1993; 171: 223–229.
20. Galkina E, Ley K. Vascular adhesion molecules in atherosclero-
sis. Arterioscler Thromb Vasc Biol, 2007; 27: 2292–2301.
21. Kitagawa K, Matsumoto M, Sasaki T et al. Involvement of
ICAM-1 in the progression of atherosclerosis in APOE-knockout
mice. Atherosclerosis, 2002; 160: 305–310.
22. Lutgens E, Gorelik L, Daemen MJ et al. Requirement for CD154
in the progression of atherosclerosis. Nat Med, 1999; 5: 1313–1316.
23. Pepper MS. Role of the matrix metalloproteinase and plasmino-
gen activator-plasmin systems in angiogenesis. Arterioscler
Thromb Vasc Biol, 2001; 21: 1104–1117.
24. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression
of matrix metalloproteinases and matrix degrading activity in
vulnerable regions of human atherosclerotic plaques. J Clin
Invest, 1994; 94: 2493–2503.
25. Preissner KT, Kanse SM, May AE. Urokinase receptor: A mo-
lecular organizer in cellular communication. Curr Opin Cell Biol,
2000; 12: 621–628.
26. Maron DJ, Fazio S, Linton MF. Current perspectives on statins.
Circulation, 2000; 101: 207–213.
27. Endo A. The discovery and development of HMG-CoA reduc-
tase inhibitors. J Lipid Res, 1992; 33: 1569–1582.
28. Bellosta S, Bernini F, Ferri N et al. Direct vascular effects of
HMG-CoA reductase inhibitors. Atherosclerosis, 1998; 137
(suppl.): S101–S109.
29. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al.
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibi-
tors, atorvastatin and simvastatin, on the expression of endothe-
lin-1 and endothelial nitric oxide synthase in vascular endothe-
lial cells. J Clin Invest, 1998; 101: 2711–2719.
28
Cardiology Journal 2012, Vol. 19, No. 1
www.cardiologyjournal.org
30. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of
cholesterol-lowering therapy on the coronary endothelium in
patients with coronary artery disease. N Engl J Med, 1995; 332:
481–487.
31. Rezaie-Majd A, Prager GW, Bucek RA et al. Simvastatin reduc-
es the expression of adhesion molecules in circulating mono-
cytes from hypercholesterolemic patients. Arterioscler Thromb
Vasc Biol, 2003; 23: 397–403.
32. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of hu-
man endothelial cells derived from umbilical veins. Identifica-
tion by morphologic and immunologic criteria. J Clin Invest,
1973; 52: 2745–2756.
33. Gimbrone MA, Jr. Culture of vascular endothelium. Prog He-
most Thromb, 1976; 3: 1–28.
34. Gawaz M, Neumann FJ, Dickfeld T et al. Activated platelets
induce monocyte chemotactic protein-1 secretion and surface
expression of intercellular adhesion molecule-1 on endothelial
cells. Circulation, 1998; 98: 1164–1171.
35. Dickfeld T, Lengyel E, May AE et al. Transient interaction of
activated platelets with endothelial cells induces expression of
monocyte-chemoattractant protein-1 via a p38 mitogen-activated
protein kinase mediated pathway. Implications for atherogenesis.
Cardiovasc Res, 2001; 49: 189–199.
36. May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M.
Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets
upregulates CD40L and triggers CD40L-dependent matrix degra-
dation by endothelial cells. Circulation, 2002; 106: 2111–2117.
37. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins
selectively inhibit leukocyte function antigen-1 by binding to
a novel regulatory integrin site. Nat Med, 2001; 7: 687–692.
38. Yoshida M, Sawada T, Ishii H et al. HMG-CoA reductase inhibitor
modulates monocyte-endothelial cell interaction under physio-
logical flow conditions in vitro: Involvement of Rho GTPase-
-dependent mechanism. Arterioscler Thromb Vasc Biol, 2001;
21: 1165–1171.
39. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-
-term effects of pravastatin on plasma concentration of C-reactive
protein. The Cholesterol and Recurrent Events (CARE) Investi-
gators. Circulation, 1999; 100: 230–235.
40. Mulhaupt F, Matter CM, Kwak BR et al. Statins (HMG-CoA
reductase inhibitors) reduce CD40 expression in human vascu-
lar cells. Cardiovasc Res, 2003; 59: 755–766.
41. Wagner AH, Gebauer M, Guldenzoph B, Hecker M. 3-hydroxy-
-3-methylglutaryl coenzyme A reductase-independent inhibition
of CD40 expression by atorvastatin in human endothelial cells.
Arterioscler Thromb Vasc Biol, 2002; 22: 1784–1789.
42. Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin
modulates chemokine and chemokine receptor expression by
geranylgeranyl isoprenoid pathway in human endothelial cells
and macrophages. Atherosclerosis, 2006; 188: 51–58.
43. Mosheimer BA, Kaneider NC, Feistritzer C et al. Cd40-ligand-
-dependent induction of COX-2 gene expression in endothelial
cells by activated platelets: Inhibitory effects of atorvastatin.
Blood Coagul Fibrinol, 2005; 16: 105–110.
44. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive
protein in ”active” coronary artery disease. Am J Cardiol, 1990;
65: 168–172.
45. Osman L, Amrani M, Ilsley C, Yacoub MH, Smolenski RT.
Atorvastatin accelerates extracellular nucleotide degradation
in human endothelial cells. Mol Cell Biochem, 2008; 308: 209–217.
46. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative
dose efficacy study of atorvastatin versus simvastatin, pravasta-
tin, lovastatin, and fluvastatin in patients with hypercholester-
olemia (the CURVES study). Am J Cardiol, 1998; 81: 582–587.
47. Jones PH, Davidson MH, Stein EA et al. Comparison of the
efficacy and safety of rosuvastatin versus atorvastatin, simvastatin,
and pravastatin across doses (STELLARr* trial). Am J Cardiol,
2003; 92: 152–160.
48. Gentile S, Turco S, Guarino G et al. Comparative efficacy study
of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo
in type 2 diabetic patients with hypercholesterolaemia. Diabetes
Obes Metab, 2000; 2: 355–362.
49. Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D,
Cziraky M. Comparison of cardiovascular event rates in pa-
tients without cardiovascular disease in whom atorvastatin or
simvastatin was newly initiated. Mayo Clin Proc, 2008; 83:
1316–1325.
50. Lacroix R, Sabatier F, Mialhe A et al. Activation of plasminogen
into plasmin at the surface of endothelial microparticles: A mecha-
nism that modulates angiogenic properties of endothelial pro-
genitor cells in vitro. Blood, 2007; 110: 2432–2439.
51. Patti G, Chello M, Gatto L et al. Short-term atorvastatin preload
reduces levels of adhesion molecules in patients with acute cor-
onary syndrome undergoing percutaneous coronary interven-
tion. Results from the ARMYDA-ACS CAMs (Atorvastatin for
Reduction of Myocardial Damage during Angioplasty-Cell Adhe-
sion Molecules) substudy. J Cardiovasc Med (Hagerstown),
2010; 11: 795–800.
